-
ARD: Anifrolumab efficacy and safety according to type I interferon gene signature and clinical subgroups in SLE patients: a post hoc analysis of pooled data from two phase III trials
Time of Update: 2022-04-23
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
-
JAMA Dermatol: Comparison of the efficacy of systemic immunomodulatory therapy for atopic dermatitis
Time of Update: 2022-04-23
Systemic immunomodulators used to treat atopic dermatitis include cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and dupilumab, abrutinib, braziltinib, tralotinib Kinumab and upadacitinib were recently approved in different countries .
7; high certainty) was associated with lower EASI slightly than dupilumab, 600 mg, then 300 mg every 2 weeks .
-
Read the article, idiopathic inflammatory myopathy: classification, pathological manifestations and treatment
Time of Update: 2022-04-22
Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases, often characterized by chronic myositis, with variable clinical manifestations, treatment response, and prognosis .
-
ARD: Analysis of cord blood levels of TNF inhibitors to validate EULAR recommendations for TNF inhibitor use during pregnancy
Time of Update: 2022-04-22
Based on limited evidence, the European League of Rheumatology Associations (EULAR) recommends discontinuation of adalimumab and infliximab at 20 weeks of gestational age and etanercept at 30-32 weeks of gestational age, and conditional continue to use certolizumab polyethylene glycol .
-
ARD: Incidence and risk of serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors
Time of Update: 2022-04-18
Although the results need to be interpreted with caution given the many important differences between the RA and PsA populations, the findings suggest that clinicians should consider a diagnosis of rheumatism when initiating TNFi therapy and assessing a patient's risk for future serious infections .
-
Rheumatology: Shared-decision-based treatment options for patients with rheumatoid arthritis in remission in the FREE-J study
Time of Update: 2022-04-18
At the end of Phase 2, a similar proportion of patients in the MTX group maintained DAS28(erythrocyte sedimentation rate) <2.
6 (continue or downgrade), but this proportion in the bDMARD-discontinuation group was significantly lower than DAS28(erythrocyte sedimentation rate) <2.
-
J Immunother Cancer: Association of lower autoantibody levels with immune-related adverse events caused by immune checkpoint inhibitors
Time of Update: 2022-04-18
Source: Ghosh N, Postow M, Zhu C, Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
J Immunother Cancer 2022 01;10(1)Ghosh N, Postow M, Zhu C,Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.
-
J Am Acad Dermatol: Real-World Experience with Ustekinumab in the Treatment of Plaque Psoriasis in Children
Time of Update: 2022-04-18
Our knowledge of the efficacy and safety of ustekinumab in children with plaque psoriasis is limited to two Phase 3 clinical trials, to assess the real-world experience of this biologic in children and adolescents, one of our Calgary, Canada A community dermatology clinic conducted a retrospective chart review .
-
ARD: Distinctive circulating miRNA profiles highlight thromboinflammation in Behçet syndrome
Time of Update: 2022-04-18
role in the diagnosis of vascular and immune -mediated diseases, both as potential candidate biomarkers and as pathogenic pathway clues .
Immunization To search for new biomarkers for BS diagnosis, this study measured ci-miRNA profiles in BS patients compared with healthy controls ( HC) .
-
ARD: Efficacy of COVID-19 vaccines in patients taking immunosuppressants
Time of Update: 2022-04-18
In individuals taking immunosuppressants, the researchers found: ( 1 ) Vaccination reduced the risk of SARS-CoV-2 infection ( aHR=0.
In individuals taking immunosuppressants, the researchers found: ( 1 ) Vaccination reduced the risk of SARS-CoV-2 infection ( aHR=0.
-
Expert Opin Investig Drugs: Disease Improvement in Ankylosing Spondylitis Treated with TNF Inhibitors
Time of Update: 2022-04-18
Source: Garcia-Montoya L, Emery P, Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.
Expert Opin Investig Drugs 2021 Nov;30(11)Garcia-Montoya L, Emery P, Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.
-
Transl Res: CD11b agonists--a new method for the treatment of lupus nephritis
Time of Update: 2022-04-18
We also combine the findings of several recent studies showing that these ITGAM SNPs lead to a weaker ability of CD11b protein to inhibit TLR-dependent pro-inflammatory pathways in leukocytes, and that activation of CD11b by novel small-molecule agonists inhibits TLR-dependent pathways, These include reducing circulating levels of interferon I and anti-dsDNA antibodies, and reducing CD11b activation in LN in model systems .
-
EBioMedicine: Modulating effects of alcohol exposure during pregnancy and pubertal stress on arthritic responses in adult female rats
Time of Update: 2022-04-18
Study overview 1: Pregnant dams were fed (liquid ethanol or pelleted controls) during pregnancy (GD1-21); 2: Adolescent females were exposed to chronic mild stress (CMS) or not from p31?41 onwards Interference (Non-CMS); 3: Adult rats (p55-60) were injected intradermally with complete Freund's adjuvant (CFA) or saline in the tail; 4: Joint assessment on days 5, 9, 11, 13, 15 severity of inflammation .
-
Clin Oral Investig: Diode Laser is an Effective and Safe Treatment for Behçet's Disease-Associated Oral Ulcers
Time of Update: 2022-04-18
A randomized trial published today in Clin Oral Investig evaluated the efficacy of diode laser therapy compared with topical corticosteroids in the treatment of oral ulcers associated with Behçet's disease .
-
JAMA Dermatol: visual clues for the histopathological diagnosis of psoriasis
Time of Update: 2022-04-18
To evaluate the effectiveness of ñsign in daily clinical practice, we randomly selected patients (case group) with a histological diagnosis of psoriasis in our hospital database (November 1, 2021) or those with a previous diagnosis other than psoriasis Biopsy specimens of skin lesions from patients with inflammatory skin disease (control group) .
-
EHJCP: Cardiorenal risk comparison of celecoxib versus naproxen or ibuprofen for arthritis
Time of Update: 2022-04-18
24,081 patients requiring NSAIDs for osteoarthritis or rheumatoid arthritis and at increased cardiovascular risk were randomized to receive celecoxib, ibuprofen, or naproxen .
The current prespecified secondary analysis assessed the incidence of prespecified composite cardiorenal outcomes [adjudicated renal events, hospitalization for congestive heart failure (CHF), or hospitalization for hypertension (HTN)] in the intent-to-treat (ITT) population.
-
J Dermatolog Treat: Budalumab effective in scalp/nail psoriasis
Time of Update: 2022-04-18
In AMAGINE-2/3, patients receiving budaluzumab 210 mg Q2W or ustekinumab for 52 consecutive weeks reported nail clearance as measured by the Nail Psoriasis Severity Index (NAPSI) .
-
ARD: Anti-RNP antibodies in systemic lupus erythematosus are associated with an interferon gene signature independent of reduced complement levels
Time of Update: 2022-04-18
To elucidate the interrelationship of specific antinuclear antibodies (ANA) , complement and interferon gene signature (IGS) in the pathogenesis of systemic lupus erythematosus (SLE) .
-
Eur Rev Med Pharmacol Sci: A real-world study of edoxaban in the treatment of venous thromboembolism/pulmonary embolism in lupus anticoagulant-positive patients during the COVID-19 pandemic lockdown in Italy
Time of Update: 2022-04-18
Changes in biochemical parameters during the observation periodAnalysis conclusionresearch conclusion research conclusionEdoxaban is safe and effective for the prevention and treatment of VTE/PE recurrence in LAC-positive patients without arterial events .
-
ARD: EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Time of Update: 2022-04-18
Purpose: For gout, vasculitis, systemic sclerosis (SSc) , myositis, mixed connective tissue disease (MCTD) , Sjögren's syndrome (SS) , systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) Develop recommendations for cardiovascular risk (CVR) management .
